Q2 EPS Estimates for Aurora Cannabis Lowered by Roth Capital

Key Points

• Roth Capital has downgraded its Q2 2026 EPS estimate for Aurora Cannabis from $0.32 to $0.16, while the consensus for the full year is forecasted at (0.22) per share.
• Aurora Cannabis stock opened at C$6.17 and has a market cap of C$337.55 million, with a current PE ratio of -7.62.
• Senior Officer Andre Jerome purchased 8,000 shares of Aurora Cannabis stock at an average price of C$5.83 each, indicating confidence in the company's future.

Aurora Cannabis Inc. (TSE:ACB - Free Report) - Research analysts at Roth Capital cut their Q2 2026 EPS estimates for shares of Aurora Cannabis in a note issued to investors on Wednesday, August 6th. Roth Capital analyst W. Kirk now anticipates that the company will post earnings of $0.16 per share for the quarter, down from their prior forecast of $0.32. The consensus estimate for Aurora Cannabis' current full-year earnings is ($0.22) per share. Roth Capital also issued estimates for Aurora Cannabis' Q3 2026 earnings at $0.81 EPS and Q4 2026 earnings at ($0.13) EPS.

Aurora Cannabis Stock Performance

Shares of Aurora Cannabis stock opened at C$6.17 on Monday. The company has a 50 day moving average of C$6.54 and a 200-day moving average of C$6.71. Aurora Cannabis has a 1-year low of C$4.95 and a 1-year high of C$9.90. The company has a current ratio of 3.42, a quick ratio of 2.48 and a debt-to-equity ratio of 18.72. The company has a market cap of C$337.55 million, a PE ratio of -7.62 and a beta of 2.71.

Insider Buying and Selling at Aurora Cannabis

In other news, Senior Officer Andre Jerome purchased 8,000 shares of the business's stock in a transaction dated Friday, June 20th. The stock was bought at an average price of C$5.83 per share, with a total value of C$46,640.00.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.